SIROLIMUS ELUTING STENT IS SUPERIOR TO PACLITAXEL ELUTING STENT IN PATIENTS WITH CHRONIC RENAL INSUFFICIENCY.  by Ann, Soe Hee et al.
E1085
JACC April 5, 2011
Volume 57, Issue 14
  MYOCARDIAL ISCHEMIA AND INFARCTION 
SIROLIMUS ELUTING STENT IS SUPERIOR TO PACLITAXEL ELUTING STENT IN PATIENTS WITH CHRONIC 
RENAL INSUFFICIENCY.
ACC Poster Contributions
Ernest N. Morial Convention Center, Hall F
Monday, April 04, 2011, 3:30 p.m.-4:45 p.m.
Session Title: ACS Comorbidities and Outcome
Abstract Category: 4. Unstable Ischemic Syndrome/Long-Term Outcome
Session-Poster Board Number: 1106-373
Authors: Soe Hee Ann, Chan Joon Kim, Soo Yeon Jung, Tae Hoon Kim, Suk Min Seo, Mahn Won Park, Yun Seok Choi, Chan Seok Park, Hun Jun Park, Chul 
Soo Park, Keon Yoong Moon, Kiyuk Chang, Hee Yeol Kim, Ki Dong Yoo, Wook Sung Chung, Ki-Bae Seung, Seoul St. Mary’s hospital, Seoul, South Korea
Background:  Patients with chronic renal insufficiency (CRI) have been reported having high incidence of major adverse cardiac event (MACE) 
after percutaneous coronary intervention (PCI). In several randomized trial, sirolimus eluting stent (SES) showed fewer 9 month MACE than paclitaxel 
eluting stent (PES). So, this study is aimed to compare SES and PES in patients with CRI.
Methods:  Consecutive 9292 patients received PCI in 8 hospitals of catholic medical center from January 2004 to December 2009. We analyzed 
1281 patients with CRI. CRI was defined as estimated Glomerular filtration rate (GFR) below 60ml/min/1.73m2 by MDRD methods. In these 
patients, SES group was 611(67.8%) and PES group was 290 (32.2%). Primary object was composite of MACE including death, myocardial infarction 
(MI), and revascularization of target lesion and vessel (TLR/TVR).
Results:  In baseline characteristics, men proportion, previous MI, previous PCI and acute coronary syndrome (ACS) were more in PES group. 
SES group had higher LDL cholesterol and higher ejection fraction than PES group. During follow up period (median 801 days), as compared with 
SES group, PES group had more composite of MACE (20.3% vs. 32.1%), all cause of death (10.8% vs. 18.6%) and TLR/TVR (9.5% vs. 14.1%). The 
low efficacy of PES was pronounced in terms of MACE (adjusted hazard ratio 1.94, 95% confidence interval 1.364-2.80, p<0.001) by Cox hazard 
regression analysis. 
Conclusions:  SES is superior to PES with respect to MACE in patients with CRI. 
